September 30, 2024
Chevron deference was established by the 1984 Supreme Court of the United States (SCOTUS) case of Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., which related to EPA’s ability to regulate air quality under the Clean Air Act. The decision mandated that federal courts defer to federal agency’s reasonable interpretation of ambiguous statutes...
Read MoreRyan M. Hohman, JD, VP of Public Affairs, Friends of Cancer Research | September 5, 2024
Chevron deference was established by the 1984 Supreme Court of the United States (SCOTUS) case of Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., which related to EPA’s ability to regulate air quality under the Clean Air Act. The decision mandated that federal courts defer to federal agency’s reasonable interpretation of ambiguous statutes...
Read MoreAugust 30, 2024
Friends of Cancer Research (Friends) is pleased to announce the publication of our new perspective on the significance of pragmatic clinical trials (PCTs) in ESMO Real World Data and Digital Oncology. PCTs evaluate the effectiveness of interventions in settings that more closely resemble real-world care, aiming to produce evidence directly applicable to clinical practice. Recognizing…
Read MoreJuly 26, 2024
Emerging data from clinical trials evaluating the use of immune checkpoint inhibitors (ICI) as part of adjuvant, neoadjuvant, and perioperative regimens indicate improved outcomes for patients with resectable non-small cell lung cancer (NSCLC), including early data suggesting a survival benefit. Perioperative treatment encompasses the entire period surrounding surgery, with neoadjuvant therapy administered before surgery and…
Read MoreJune 11, 2024
Testimony for the hearing noted the recent authorities provided through the Food and Drug Omnibus Reform Act of 2022 (FDORA) designed to enhance the accelerated approval program and ensure timely generation of confirmatory evidence.
Read MoreJune 10, 2024
Chris White is a passionate advocate for cell therapies. He spends his time collaborating with patient advocacy groups, philanthropy organizations, and industry stakeholders focused on melanoma and cell therapy.
Read MoreMay 28, 2024
On May 23rd, Friends of Cancer Research hosted a public webinar, “Friends’ Cell Therapies Webinar for Advocates,” spotlighting the pivotal role of patient advocacy and cell and gene therapies in cancer care. Dr. Alex Marson from Gladstone Institutes presented CRISPR’s potential in cancer immunotherapy, while Chris White, author and patient advocate, shared his journey with metastatic melanoma and the success of a tumor-infiltrating lymphocytes (TIL) therapy trial, emphasizing the impact of cell therapies in remission. The webinar bridged the gap between research and tangible patient outcomes by facilitating an open dialogue and an engaging Q&A session between the live audience and panelists.
Read MoreBrittany Avin McKelvey, PhD | May 20, 2024
While significant progress has been made in cancer treatment and care, this progress has not always easily translated to new treatments for pediatric oncology patients. In 2003, the Pediatric Research Equity Act (PREA) passed requiring the study of cancer therapeutics in certain pediatric cases.
Read MoreMay 13, 2024
On May 6th, Friends of Cancer Research and Parker Institute for Cancer Immunotherapy hosted a public meeting, “Unlocking Complex Cell-Based Therapies,” to discuss innovative frameworks and proposals for enhancing the safety, expansion, and activity of the next generation of cell-based gene therapies. Panels addressed operational and biological challenges to advancing cell and gene therapies, novel approaches to clinical trials, the expansion of cell therapies for solid tumors, and included patient insights and experiences with these complex therapies.
Read MoreMarch 19, 2024
Digital and computational pathology platforms have the potential to provide more precise and novel diagnostic insights to inform treatment decision making and, ultimately, improve patient outcomes. Friends of Cancer Research (Friends) is leading a new research partnership, the Digital and Computational Pathology Tool Harmonization (Digital PATH) Project, to support robust development of digital and computational pathology platforms for use in oncology drug development.
Read More
